Van Os NJH, Chessa L, Weemaes CMR, Van Deuren M, Fiévet A, Van Gaalen J et al. Genotype-phenotype correlations in ataxia telangiectasia patients with ATM c.3576G > A and c.8147T > C mutations. J Med Genet. 2019.

Zaki-Dizaji M, Akrami SM, Abolhassani H, Rezaei N, Aghamohammadi A. Ataxia telangiectasia syndrome: moonlighting ATM. Expert Rev Clin Immunol. 2017;13(12):1155–72.

Article  CAS  PubMed  Google Scholar 

Lavin MF, Shiloh Y. The genetic defect in Ataxia-Telangiectasia. Annu Rev Immunol. 1997;15(1):177–202.

Article  CAS  PubMed  Google Scholar 

Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016.

Fattahi Z, Beheshtian M, Mohseni M, Poustchi H, Sellars E, Nezhadi SH et al. Iranome: a catalog of genomic variations in the Iranian population. Hum Mutat. 2019.

Cooper TJ, Wardell K, Garcia V, Neale MJ. Homeostatic regulation of meiotic DSB formation by ATM/ATR. Exp Cell Res. 2014.

Weitering TJ, Takada S, Weemaes CMR, van Schouwenburg PA, van der Burg M. ATM: translating the DNA damage response to adaptive immunity. Trends in Immunology; 2021.

Wang Q, Chen Y, Chang H, Hu T, Wang J, Xie Y et al. The role and mechanism of ATM-Mediated autophagy in the Transition from Hyper-Radiosensitivity to Induced Radioresistance in Lung Cancer under Low-Dose Radiation. Front Cell Dev Biol. 2021.

Chaudhary MW, Al-Baradie RS. Ataxia-telangiectasia: future prospects. Application Clin Genet. 2014.

Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair. 2016.

Samara A, Gusman M, Aker L, Parsons MS, Mian AY, Eldaya RW. The Forgotten Phacomatoses: a neuroimaging review of Rare Neurocutaneous disorders. Curr Probl Diagn Radiol. 2022.

Zaki-Dizaji M, Akrami SM, Azizi G, Abolhassani H, Aghamohammadi A. Inflammation, a significant player of Ataxia–telangiectasia pathogenesis? Inflamm Res. 2018;67(7):559–70.

Article  CAS  PubMed  Google Scholar 

Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol; 2003.

Satitsuksanoa P, Daanje M, Akdis M, Boyd SD, van de Veen W. Biology and dynamics of B cells in the context of IgE-mediated food allergy. Allergy: Eur J Allergy Clin Immunol. 2021.

Mohammadinejad P, Abolhassani H, Aghamohammadi A, Pourhamdi S, Ghosh S, Sadeghi B, et al. Class switch recombination process in Ataxia Telangiectasia patients with elevated serum levels of IgM. J Immunoass Immunochem. 2015;36(1):16–26.

Article  CAS  Google Scholar 

Banerji J, Olson L, Schaffner W. A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes. Cell. 1983.

Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull. 2007;81–82(1):129–47.

Article  PubMed  Google Scholar 

Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14(668).

Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, et al. Safety and Effectiveness of Long-Term Intravenous Administration of Edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121.

Article  PubMed  Google Scholar 

Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, et al. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2019;380(17):1597–605.

Article  CAS  PubMed  Google Scholar 

Amirifar P, Mozdarani H, Yazdani R, Kiaei F, Moeini Shad T, Shahkarami S, et al. Effect of class switch recombination defect on the phenotype of Ataxia-telangiectasia patients. Immunol Invest. 2021;50(2–3):201–15.

Article  CAS  PubMed  Google Scholar 

Abolhassani H, Kiaee F, Tavakol M, Chavoshzadeh Z, Mahdaviani SA, Momen T et al. Fourth update on the Iranian National Registry of primary immunodeficiencies: integration of molecular diagnosis. J Clin Immunol. 2018.

Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J et al. The European Society for Immunodeficiencies (ESID) Registry Working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunology: Pract. 2019.

Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. J Allergy Clin Immunol. 2018;141(4):1450–8.

Article  CAS  PubMed  Google Scholar 

Amirifar P, Ranjouri MR, Pashangzadeh S, Lavin M, Yazdani R, Moeini Shad T, et al. The spectrum of ATM gene mutations in Iranian patients with ataxia-telangiectasia. Pediatr Allergy Immunol. 2021;32(6):1316–26.

Article  CAS  PubMed  Google Scholar 

Amirifar P, Mehrmohamadi M, Ranjouri MR, Akrami SM, Rezaei N, Saberi A et al. Genetic risk variants for Class switching recombination defects in Ataxia-Telangiectasia patients. J Clin Immunol. 2022.

Aghamohammadi A, Rezaei N, Yazdani R, Delavari S, Kutukculer N, Topyildiz E et al. Consensus Middle East and North Africa Registry on Inborn errors of immunity. J Clin Immunol. 2021.

Reiman A, Srinivasan V, Barone G, Last JI, Wootton LL, Davies EG et al. Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer. 2011.

Dörk T, Bendix-Waltes R, Wegner RD, Stumm M. Slow progression of Ataxia-Telangiectasia with double missense and in Frame splice mutations. Am J Med Genet. 2004.

Moeini Shad T, Yazdani R, Amirifar P, Delavari S, Heidarzadeh Arani M, Mahdaviani SA et al. Atypical Ataxia Presentation in Variant Ataxia Telangiectasia: Iranian Case-Series and Review of the Literature. Vol. 12, Frontiers in immunology. Switzerland; 2021. p. 779502.

Micol R, Slama L, Ben, Suarez F, Le Mignot L, Beauté J, Mahlaoui N, et al. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol. 2011;128(2):382–9.

Article  PubMed  Google Scholar 

Zielen S, Duecker RP, Woelke S, Donath H, Bakhtiar S, Buecker A, et al. Simple measurement of IgA predicts immunity and mortality in Ataxia-Telangiectasia. J Clin Immunol. 2021;41(8):1878–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reichenbach J, Schubert R, Feinberg J, Beck O, Rosewich M, Rose MA, et al. Impaired interferon-γ production in response to live bacteria and toll-like receptor agonists in patients with ataxia telangiectasia. Clin Exp Immunol. 2006;146(3):381–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aghamohammadi A, Imai K, Moazzami K, Abolhassani H, Tabatabaeiyan M, Parvaneh N et al. Ataxia-Telangiectasia in a Patient Presenting With Hyper-immunoglobulin M Syndrome A Aghamohammadi. Vol. 20, J Investig Allergol Clin Immunol. 2010. Available from: www.ncbi.nlm.nih.gov/snp

Ghiasy S, Parvaneh L, Azizi G, Sadri G, Zaki dizaji M, Abolhassani H, et al. The clinical significance of complete class switching defect in Ataxia telangiectasia patients. Expert Rev Clin Immunol. 2017;13(5):499–505.

Article  CAS  PubMed  Google Scholar 

van Os NJH, Jansen AFM, van Deuren M, Haraldsson A, van Driel NTM, Etzioni A, et al. Ataxia-telangiectasia: Immunodeficiency and survival. Clin Immunol. 2017;178:45–55.

Article  PubMed  Google Scholar 

Panchakshari RA, Zhang X, Kumar V, Du Z, Wei PC, Kao J, et al. DNA double-strand break response factors influence end-joining features of IgH class switch and general translocation junctions. Proc Natl Acad Sci U S A. 2018;115(4):762–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lumsden JM, McCarty T, Petiniot LK, Shen R, Barlow C, Wynn TA, et al. Immunoglobulin class switch recombination is impaired in atm-deficient mice. J Exp Med. 2004;200(9):1111–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demirdag YY, Gupta S. Update on infections in primary antibody deficiencies. Front Immunol. 2021;12:634181.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verhagen MMM, Last JI, Hogervorst FBL, Smeets DFCM, Roeleveld N, Verheijen F, et al. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat. 2012;33(3):561–71.

Article  CAS  PubMed  Google Scholar 

Taylor P, Li Y, Camp S, Rachinsky TL, Ekström T, Getman D, et al. Structure and regulation of expression of the acetylcholinesterase gene. Chem Biol Interact. 1993;87(1–3):199–207.

Article  CAS  PubMed  Google Scholar 

Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene. 2007;26(56):7741–8.

Article  CAS  PubMed  Google Scholar 

Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene. 2007;26(56):7749–58.

Article  CAS  PubMed  Google Scholar 

Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009;23(16):1895–909.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee HJ, Lan L, Peng G, Chang WC, Hsu MC, Wang YN, et al. Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response. Cell Res. 2015;25(2):225–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X, Liu M, Bai J, Xu J, Zhu C, Dong J et al. ATR kinase activity promotes antibody class switch recombination in B cells through cell cycle regulation without suppressing DSB resection and microhomology usage. J Leukoc Biol. 2021.

Shimura N, Kojima S. The Lowest Radiation Dose having molecular changes in the living body. Dose Response. 2018;16(2):1559325818777326.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruine de Bruin L, Schuuring E, de Bock GH, Slagter-Menkema L, Mastik MF, Noordhuis MG, et al. High pATM is Associated with Poor Local Control in Supraglottic Cancer treated with Radiotherapy. Laryngoscope. 2020;130(8):1954–60.

Article  CAS  PubMed  PubMed Central